The University of Rochester Cancer Center is a multidisciplinary Center with broad responsibilities for clinical research, primary and consultative interdisciplinary care, and conduct of coordinated programs in cancer education, nursing and basic research. Clinical research and treatment in the Center is community based and involves a consortium of five general hospitals in Monroe County and affiliated hospitals in the Finger Lakes region. Clinical research emphasizes combined modalities and cooperative group trials and includes participation in R.T.O.G., E.C.O.G., PSYCOG, C.C.S.G., and G.O.G. An in-house clinical investigations committee translates basic research advances into clinical research. Basic research is focused in fields particularly relevant to treatment advances. The integrating research theme of the Center is the comparative study of damage and repair of macromolecules and organelles critical to cell survival (DNA, RNA, and membranes) and the influence of these on treatment. Biostatistics-Epidemiology-Registry, Experimental Pathology/Ultrastructural, Centrifugal Elutriation, and the Animal Tumor Research Facilities serve as broad, shared resources of the Center. Complementing the core research programs are cancer control and cancer education programs. The Center is, thus, not only as a community, regional, and national clinical research resource, but also a resource for basic research and for the development of education and cancer control models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA011198-17
Application #
3101267
Study Section
(SRC)
Project Start
1978-02-01
Project End
1986-01-31
Budget Start
1985-02-01
Budget End
1986-01-31
Support Year
17
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Medicine
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Wei, C; Callahan, B P; Turner, M J et al. (1998) Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes. Int J Mol Med 2:487-96
Ford, H L; Silver, D L; Kachar, B et al. (1997) Effect of Mts1 on the structure and activity of nonmuscle myosin II. Biochemistry 36:16321-7
Fieler, V K (1997) Side effects and quality of life in patients receiving high-dose rate brachytherapy. Oncol Nurs Forum 24:545-53
Johnson, J E; Fieler, V K; Wlasowicz, G S et al. (1997) The effects of nursing care guided by self-regulation theory on coping with radiation therapy. Oncol Nurs Forum 24:1041-50
Johnson, J E (1996) Coping with radiation therapy: optimism and the effect of preparatory interventions. Res Nurs Health 19:3-12
Sandhu, F A; Kim, Y; Lapan, K A et al. (1996) Expression of the C terminus of the amyloid precursor protein alters growth factor responsiveness in stably transfected PC12 cells. Proc Natl Acad Sci U S A 93:2180-5
Fieler, V K; Borch, A (1996) Results of a patient education project using a touch-screen computer. Cancer Pract 4:341-5
Dragone, L L; Barth, R K; Sitar, K L et al. (1995) Disregulation of leukosialin (CD43, Ly48, sialophorin) expression in the B-cell lineage of transgenic mice increases splenic B-cell number and survival. Proc Natl Acad Sci U S A 92:626-30
Ford, H L; Salim, M M; Chakravarty, R et al. (1995) Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene 11:2067-75
Ford, H L; Zain, S B (1995) Interaction of metastasis associated Mts1 protein with nonmuscle myosin. Oncogene 10:1597-605

Showing the most recent 10 out of 49 publications